PE
PEN.US Penumbra Inc
- Market cap
- USD 12.6B
- P/E
- 80.8x
- P/B
- 7.99x
- ROE
- 9.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PEN.US undervalued?
Graham numberThe Graham number of Penumbra Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Penumbra Inc fundamental analysis
No fundamental analysis for Penumbra Inc yet.
Penumbra Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide cathete…
Full company profilePenumbra Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Penumbra Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 263M | 334M | 445M | 547M | 560M | 748M | 847M | 1.06B | 1.19B | 1.40B | 1.57B |
| Gross Profit | 171M | 217M | 293M | 372M | 338M | 475M | 535M | 683M | 755M | 942M | 1.06B |
| Operating Income | -1.35M | 1.17M | -852K | 47.5M | -38.9M | -7.50M | 6.08M | 73.6M | 86.2M | 189M | 173M |
| EBITDA | 947K | 4.95M | 36.2M | 55.6M | -26.1M | 8.91M | 30.0M | 109M | 46.0M | 224M | 214M |
| Net Income | 14.8M | 4.66M | 6.60M | 48.5M | -19.3M | 2.62M | -2.00M | 91.0M | 14.0M | 178M | 146M |
| EPS | 0.44 | 0.13 | 0.18 | 1.34 | -0.54 | 0.07 | -0.05 | 2.32 | 0.36 | 4.52 | 3.69 |
| Balance Sheet | |||||||||||
| Total Assets | 308M | 477M | 515M | 666M | 823M | 1.24B | 1.37B | 1.56B | 1.53B | 1.83B | 2.03B |
| Total Liabilities | 41.7M | 76.3M | 92.6M | 180M | 185M | 290M | 372M | 377M | 382M | 399M | 442M |
| Shareholders' Equity | 267M | 400M | 422M | 486M | 641M | 954M | 999M | 1.18B | 1.15B | 1.43B | 1.58B |
| Cash & Short-term Investments | 129M | 215M | 201M | 189M | 265M | 255M | 188M | 289M | 340M | 545M | 674M |
| Total Debt | - | - | - | 82.3M | 77.3M | 174M | 236M | 234M | 223M | 220M | 209M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.8M | 12.7M | 28.8M | 26.7M | -33.2M | 9.50M | -55.7M | 97.3M | 168M | 239M | 233M |
| Capital Expenditure | 13.6M | 15.0M | 9.60M | 22.1M | 24.8M | 21.2M | 19.3M | 15.2M | 21.2M | 63.7M | 56.4M |
| Free Cash Flow | -26.4M | -2.34M | 19.2M | 4.54M | -58.0M | -11.7M | -75.0M | 82.1M | 147M | 175M | 176M |
| Ratios | |||||||||||
| ROE | 5.6% | 1.2% | 1.6% | 10.0% | -3.0% | 0.3% | -0.2% | 7.7% | 1.2% | 12.4% | 9.2% |
| ROA | 4.8% | 1.0% | 1.3% | 7.3% | -2.3% | 0.2% | -0.1% | 5.8% | 0.9% | 9.7% | 7.2% |
| Net Profit Margin | 5.6% | 1.4% | 1.5% | 8.9% | -3.4% | 0.4% | -0.2% | 8.6% | 1.2% | 12.7% | 9.3% |
| Debt to Equity | - | - | - | 0.17x | 0.12x | 0.18x | 0.24x | 0.20x | 0.19x | 0.15x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Penumbra Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 8.04M | 0.21 | - |
| 2021 | USD 15.8M | 0.42 | 603.6% |
| 2020 | USD 10.1M | 0.28 | - |
| 2019 | USD 18.5M | 0.51 | 38.2% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Nov 16, 2014.
Who owns Penumbra Inc
- Insiders 6.63%
- Institutions 87.10%
- Public & others 6.26%
- Shares outstanding 39.4M
- Free float 38.3M
Top funds holding PEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 1.42M | 3.59% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.19M | 3.01% | +0.21% | Sep 2026 |
| BlackRock Event Driven Equity Instl | 981K | 2.49% | +27.49% | Sep 2026 |
| Vanguard Small Cap Index | 842K | 2.14% | -2.01% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 468K | 1.19% | -5.06% | Sep 2026 |
| American Funds SMALLCAP World A | 413K | 1.05% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 291K | 0.74% | +1.25% | Sep 2026 |
| BSF Global Event Driven Z2 USD | 263K | 0.67% | +28.83% | Sep 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 237K | 0.60% | -0.26% | Oct 2026 |
| iShares Russell Mid-Cap Growth ETF | 214K | 0.54% | -0.07% | Oct 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 214K | 0.54% | 0.00% | Oct 2026 |
| iShares US Medical Devices ETF | 188K | 0.48% | -1.12% | Oct 2026 |
| Arbitrage R | 182K | 0.46% | +91.69% | Aug 2026 |
| Fidelity Extended Market Index | 179K | 0.45% | -6.22% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 162K | 0.41% | -0.06% | Oct 2026 |
| Fidelity Mid Cap Index | 144K | 0.37% | -0.71% | Sep 2026 |
| iShares Russell 1000 Growth ETF | 144K | 0.36% | +0.09% | Oct 2026 |
| BlackRock Health Sciences Opps Inv A | 133K | 0.34% | 0.00% | Sep 2026 |
| The Merger Fund A | 132K | 0.33% | +110.54% | Jun 2026 |
| Schwab US Mid-Cap ETF | 119K | 0.30% | +0.13% | Oct 2026 |
Top institutions holding PEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 4.30M | 10.90% | -0.76% | Jun 2026 |
| HBK INVESTMENTS L P | 1.84M | 4.66% | +12.50% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.71M | 4.34% | +0.91% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.67M | 4.23% | +0.77% | Jun 2026 |
| State Street Corp | 1.24M | 3.15% | +4.84% | Jun 2026 |
| ExodusPoint Capital Management, LP | 1.09M | 2.77% | +134.39% | Jun 2026 |
| Balyasny Asset Management LLC | 1.09M | 2.77% | +43.05% | Jun 2026 |
| JPMorgan Chase & Co | 1.07M | 2.72% | +166.12% | Jun 2026 |
| The Goldman Sachs Group Inc | 847K | 2.15% | +17.56% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 835K | 2.12% | +108.64% | Jun 2026 |
| Geode Capital Management, LLC | 796K | 2.02% | +0.13% | Jun 2026 |
| NORGES BANK | 752K | 1.91% | +607.85% | Jun 2026 |
| UBS Group AG | 704K | 1.79% | +25.61% | Jun 2026 |
| Millennium Management LLC | 701K | 1.78% | -36.20% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 592K | 1.50% | +47.46% | Jun 2026 |
| Cnh Partners, LLC | 564K | 1.43% | +33.28% | Jun 2026 |
| Whitebox Advisors, LLC | 507K | 1.29% | +13.91% | Jun 2026 |
| Capital World Investors | 480K | 1.22% | +6.41% | Jun 2026 |
| Citadel Advisors Llc | 449K | 1.14% | +121.37% | Jun 2026 |
| Neuberger Berman Group LLC | 439K | 1.11% | +44.44% | Jun 2026 |
Penumbra Inc company profile
- Company name
- Penumbra Inc
- Ticker
- PEN.US
- Exchange
- USA Stocks
- Listed since
- Sep 18, 2015
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 4,700
- Fiscal year end
- December
- Address
- One Penumbra Place, Alameda, CA, United States, 94502
- Phone
- 510 748 3200
- Website
- penumbrainc.com
About Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Penumbra Inc management
10- Mr. Adam Elsesser J.D.Co-Founder, Chairman & CEO · born 1962
- Ms. Shruthi NarayanPresident · born 1985
- Dr. Arani Bose M.D.Co-Founder & Director · born 1962
- Ms. Maggie S. YuenChief Financial Officer · born 1972
- Mr. Lambert ShiuChief Accounting Officer · born 1980
- Ms. Johanna Roberts J.D.Executive VP, General Counsel & Secretary · born 1972
- Mr. Ben SorciExecutive Vice President of Operations
- Ms. Jee Hamlyn-HarrisInvestor Relations Officer
- Mr. Ben TompkinsExecutive Vice President of Development & Compliance
- Mr. Jason Richard MillsExecutive Vice President of Strategy